Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA

Clin Infect Dis. 2022 Mar 9;74(5):905-908. doi: 10.1093/cid/ciab511.

Abstract

We report a case of resistance development toward cefiderocol in a patient with intra-abdominal and bloodstream infections caused by carbapenemase-producing Enterobacter cloacae within 21 days of cefiderocol therapy. Whole genome sequencing revealed heterogeneous mutations in the cirA gene, encoding a catecholate siderophore receptor, conferring phenotypic resistance to cefiderocol.

Keywords: Enterobacter cloacae; cirA siderophore receptor; Cefiderocol; antibiotic resistance; carbapenemase.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Cefiderocol
  • Cephalosporins
  • Enterobacter cloacae* / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Siderophores* / therapeutic use
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Carbapenems
  • Cephalosporins
  • Siderophores
  • beta-Lactamases